An Open, Dose-escalating and Dose Confirmation Trial to Evaluate the Safety and Efficacy of VGN-R09b by Intra Putamen Injection in Patients With Severe Aromatic L-amino Acid Decarboxylase (AADC) Deficiency
Latest Information Update: 05 Jun 2024
At a glance
- Drugs VGN-R09 (Primary)
- Indications Aromatic amino acid decarboxylase deficiency
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai Vitalgen BioPharma
Most Recent Events
- 31 May 2024 New trial record